Collegium’s board of directors authorized a new share repurchase program to repurchase up to $150.0 million in common stock over 18 months.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on COLL:
- Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
- Collegium announces appeal courts upholds decision on Purdue ‘961 patent
- Collegium Pharmaceutical announces $25M accelerated share repurchase program
- Collegium to Participate in Upcoming Investor Conferences
- Collegium Reports Third Quarter 2023 Financial Results
